PRECIGEN, INC. Total Contract Liability
PRECIGEN, INC. (PGEN) had Total Contract Liability of $517.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-03-25
- 2025-12-31: Contract with Customer, Liability $517.00K.
- 2025-09-30: Contract with Customer, Liability $575.00K.
- 2025-06-30: Contract with Customer, Liability $2.23M.
- 2025-03-31: Contract with Customer, Liability $2.38M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2025-12-31 | $517.00K 10-K · filed 2026-03-25 | |
| 2025-09-30 | $575.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $2.23M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $2.38M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $2.52M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $2.44M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $2.20M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $2.29M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $2.33M 10-K · filed 2025-03-19 | |
| 2023-03-31 | $1.83M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $1.84M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $1.89M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $23.19M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $25.69M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $24.51M 10-K · filed 2023-03-06 | $27.46M 10-K · filed 2022-03-01 |
| 2021-09-30 | $26.72M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $26.30M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $26.87M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $25.82M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $34.16M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $39.45M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $44.02M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $53.83M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $79.12M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $83.14M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $71.19M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $57.82M 10-K · filed 2020-03-02 | $69.76M 10-K · filed 2019-03-01 |
| 2018-09-30 | $174.98M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $236.40M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |